These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 18570366)
1. Discovery of N-(2-aminophenyl)-4-[(4-pyridin-3-ylpyrimidin-2-ylamino)methyl]benzamide (MGCD0103), an orally active histone deacetylase inhibitor. Zhou N; Moradei O; Raeppel S; Leit S; Frechette S; Gaudette F; Paquin I; Bernstein N; Bouchain G; Vaisburg A; Jin Z; Gillespie J; Wang J; Fournel M; Yan PT; Trachy-Bourget MC; Kalita A; Lu A; Rahil J; MacLeod AR; Li Z; Besterman JM; Delorme D J Med Chem; 2008 Jul; 51(14):4072-5. PubMed ID: 18570366 [TBL] [Abstract][Full Text] [Related]
2. SAR and biological evaluation of analogues of a small molecule histone deacetylase inhibitor N-(2-aminophenyl)-4-((4-(pyridin-3-yl)pyrimidin-2-ylamino)methyl)benzamide (MGCD0103). Raeppel S; Zhou N; Gaudette F; Leit S; Paquin I; Larouche G; Moradei O; Fréchette S; Isakovic L; Delorme D; Fournel M; Kalita A; Lu A; Trachy-Bourget MC; Yan PT; Liu J; Rahil J; Wang J; Besterman JM; Murakami K; Li Z; Vaisburg A Bioorg Med Chem Lett; 2009 Feb; 19(3):644-9. PubMed ID: 19114304 [TBL] [Abstract][Full Text] [Related]
3. Design and synthesis of 4-[(s-triazin-2-ylamino)methyl]-N-(2-aminophenyl)-benzamides and their analogues as a novel class of histone deacetylase inhibitors. Paquin I; Raeppel S; Leit S; Gaudette F; Zhou N; Moradei O; Saavedra O; Bernstein N; Raeppel F; Bouchain G; Fréchette S; Woo SH; Vaisburg A; Fournel M; Kalita A; Robert MF; Lu A; Trachy-Bourget MC; Yan PT; Liu J; Rahil J; MacLeod AR; Besterman JM; Li Z; Delorme D Bioorg Med Chem Lett; 2008 Feb; 18(3):1067-71. PubMed ID: 18160287 [TBL] [Abstract][Full Text] [Related]
4. Substituted N-(2-aminophenyl)-benzamides, (E)-N-(2-aminophenyl)-acrylamides and their analogues: novel classes of histone deacetylase inhibitors. Moradei O; Leit S; Zhou N; Fréchette S; Paquin I; Raeppel S; Gaudette F; Bouchain G; Woo SH; Vaisburg A; Fournel M; Kalita A; Lu A; Trachy-Bourget MC; Yan PT; Liu J; Li Z; Rahil J; MacLeod AR; Besterman JM; Delorme D Bioorg Med Chem Lett; 2006 Aug; 16(15):4048-52. PubMed ID: 16713259 [TBL] [Abstract][Full Text] [Related]
5. The histone deacetylase inhibitor MGCD0103 has both deacetylase and microtubule inhibitory activity. Chia K; Beamish H; Jafferi K; Gabrielli B Mol Pharmacol; 2010 Sep; 78(3):436-43. PubMed ID: 20538840 [TBL] [Abstract][Full Text] [Related]
6. 4-(Heteroarylaminomethyl)-N-(2-aminophenyl)-benzamides and their analogs as a novel class of histone deacetylase inhibitors. Fréchette S; Leit S; Woo SH; Lapointe G; Jeannotte G; Moradei O; Paquin I; Bouchain G; Raeppel S; Gaudette F; Zhou N; Vaisburg A; Fournel M; Yan PT; Trachy-Bourget MC; Kalita A; Robert MF; Lu A; Rahil J; Robert Macleod A; Besterman JM; Li Z; Delorme D Bioorg Med Chem Lett; 2008 Feb; 18(4):1502-6. PubMed ID: 18207391 [TBL] [Abstract][Full Text] [Related]
7. The discovery of 6-amino nicotinamides as potent and selective histone deacetylase inhibitors. Hamblett CL; Methot JL; Mampreian DM; Sloman DL; Stanton MG; Kral AM; Fleming JC; Cruz JC; Chenard M; Ozerova N; Hitz AM; Wang H; Deshmukh SV; Nazef N; Harsch A; Hughes B; Dahlberg WK; Szewczak AA; Middleton RE; Mosley RT; Secrist JP; Miller TA Bioorg Med Chem Lett; 2007 Oct; 17(19):5300-9. PubMed ID: 17761416 [TBL] [Abstract][Full Text] [Related]
8. N-(4-{[4-(1H-Benzoimidazol-2-yl)-arylamino]-methyl}-phenyl)-benzamide derivatives as small molecule heparanase inhibitors. Xu YJ; Miao HQ; Pan W; Navarro EC; Tonra JR; Mitelman S; Camara MM; Deevi DS; Kiselyov AS; Kussie P; Wong WC; Liu H Bioorg Med Chem Lett; 2006 Jan; 16(2):404-8. PubMed ID: 16246551 [TBL] [Abstract][Full Text] [Related]
9. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Fournel M; Bonfils C; Hou Y; Yan PT; Trachy-Bourget MC; Kalita A; Liu J; Lu AH; Zhou NZ; Robert MF; Gillespie J; Wang JJ; Ste-Croix H; Rahil J; Lefebvre S; Moradei O; Delorme D; Macleod AR; Besterman JM; Li Z Mol Cancer Ther; 2008 Apr; 7(4):759-68. PubMed ID: 18413790 [TBL] [Abstract][Full Text] [Related]
10. Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity. Moradei OM; Mallais TC; Frechette S; Paquin I; Tessier PE; Leit SM; Fournel M; Bonfils C; Trachy-Bourget MC; Liu J; Yan TP; Lu AH; Rahil J; Wang J; Lefebvre S; Li Z; Vaisburg AF; Besterman JM J Med Chem; 2007 Nov; 50(23):5543-6. PubMed ID: 17941625 [TBL] [Abstract][Full Text] [Related]
11. Design of chimeric histone deacetylase- and tyrosine kinase-inhibitors: a series of imatinib hybrides as potent inhibitors of wild-type and mutant BCR-ABL, PDGF-Rbeta, and histone deacetylases. Mahboobi S; Dove S; Sellmer A; Winkler M; Eichhorn E; Pongratz H; Ciossek T; Baer T; Maier T; Beckers T J Med Chem; 2009 Apr; 52(8):2265-79. PubMed ID: 19301902 [TBL] [Abstract][Full Text] [Related]
12. Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives. Suzuki T; Ando T; Tsuchiya K; Fukazawa N; Saito A; Mariko Y; Yamashita T; Nakanishi O J Med Chem; 1999 Jul; 42(15):3001-3. PubMed ID: 10425110 [TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and preliminary biological evaluation of N-hydroxy-4-(3-phenylpropanamido)benzamide (HPPB) derivatives as novel histone deacetylase inhibitors. Jiao J; Fang H; Wang X; Guan P; Yuan Y; Xu W Eur J Med Chem; 2009 Nov; 44(11):4470-6. PubMed ID: 19608304 [TBL] [Abstract][Full Text] [Related]
14. Effects of a selection of histone deacetylase inhibitors on mast cell activation and airway and colonic smooth muscle contraction. Assem el-SK; Peh KH; Wan BY; Middleton BJ; Dines J; Marson CM Int Immunopharmacol; 2008 Dec; 8(13-14):1793-801. PubMed ID: 18805511 [TBL] [Abstract][Full Text] [Related]
15. Potent histone deacetylase inhibitors: N-hydroxybenzamides with antitumor activities. Maeda T; Nagaoka Y; Kuwajima H; Seno C; Maruyama S; Kurotaki M; Uesato S Bioorg Med Chem; 2004 Aug; 12(16):4351-60. PubMed ID: 15265487 [TBL] [Abstract][Full Text] [Related]
16. Discovery of 2-(6-{[(6-fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a class I selective orally active histone deacetylase inhibitor. Moffat D; Patel S; Day F; Belfield A; Donald A; Rowlands M; Wibawa J; Brotherton D; Stimson L; Clark V; Owen J; Bawden L; Box G; Bone E; Mortenson P; Hardcastle A; van Meurs S; Eccles S; Raynaud F; Aherne W J Med Chem; 2010 Dec; 53(24):8663-78. PubMed ID: 21080647 [TBL] [Abstract][Full Text] [Related]
17. Drug evaluation: MGCD-0103, a histone deacetylase inhibitor for the treatment of cancer. Kell J Curr Opin Investig Drugs; 2007 Jun; 8(6):485-92. PubMed ID: 17621879 [TBL] [Abstract][Full Text] [Related]
18. Studies of benzamide- and thiol-based histone deacetylase inhibitors in models of oxidative-stress-induced neuronal death: identification of some HDAC3-selective inhibitors. Chen Y; He R; Chen Y; D'Annibale MA; Langley B; Kozikowski AP ChemMedChem; 2009 May; 4(5):842-52. PubMed ID: 19350613 [TBL] [Abstract][Full Text] [Related]
19. Identification of ligand features essential for HDACs inhibitors by pharmacophore modeling. Chen YD; Jiang YJ; Zhou JW; Yu QS; You QD J Mol Graph Model; 2008 Apr; 26(7):1160-8. PubMed ID: 18061500 [TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological evaluation of N-hydroxyphenylacrylamides and N-hydroxypyridin-2-ylacrylamides as novel histone deacetylase inhibitors. Thaler F; Colombo A; Mai A; Amici R; Bigogno C; Boggio R; Cappa A; Carrara S; Cataudella T; Fusar F; Gianti E; di Ventimiglia SJ; Moroni M; Munari D; Pain G; Regalia N; Sartori L; Vultaggio S; Dondio G; Gagliardi S; Minucci S; Mercurio C; Varasi M J Med Chem; 2010 Jan; 53(2):822-39. PubMed ID: 20017493 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]